Skip to main content
OpenTrials
Completed

NCT Number: NCT03205098

Evaluation of Biological Markers of Mesenteric Ischemia During an Ultra-trail

To assess the evolution of biological markers of mesenteric ischemia during ultratrail.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ultra-trail Participation Cardiovascular Diseases Digestive System Diseases Gastrointestinal Diseases Intestinal Diseases Mesenteric Ischemia Peritoneal Diseases Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU de Clermont-Ferrand

Clermont-Ferrand, Auvergne, 63003, France

About this study

During physical exercise, increased sympathetic nervous system activity redistributes blood flow from splanchnic organs to working muscles. With prolonged duration and / or intensity, the splanchnic blood flow can be reduced by 80% or more. A severely reduced of splanchnic blood flow can frequently cause gastrointestinal ischemia. This ischemia associated with reduced vagal activity probably results in changes in motility and absorption.

High symptoms are reported in 40% of runners with reflux and heartburn in 15-20% of runners. The low symptoms have an incidence of about 70% in the long runs type ultra-trail.

Biological markers such as I-FABP have been shown to be useful in the diagnosis of mesenteric ischemia.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy Voluntary Subject
  • Age > 18 years
  • Written consent
  • Subject affiliated to Social Security
  • Medical certificate (mandatory to take part in the ultra-trail)

Exclusion criteria

  • Refusal to participate
  • Subject with legal protection (guardianship, trusteeship)

Treatment and study plan

blood analysis

Biological

Blood test of biological markers of mesenteric ischemia

Primary outcomes

  1. Assess biological markers of mesenteric ischemia (IFABP)

    Time frame: at day 1

    during ultratrail.

Secondary outcomes

  1. Relationship between digestive symptoms and biological markers (IFABP).

    Time frame: at day 1

Sponsors and collaborators

Lead sponsor

University Hospital, Clermont-Ferrand

Other

Registry information

Acronym: ISKETRAIL

Important dates

Study start
2015
Primary completion
2015
Study completion
2016
First posted
Jul 2, 2017
Registry last updated
Jul 2, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.